Generics increase competition: study
The study by an MIT professor and Analysis Group researchers reportedly confirmed that the increase in generics had not reduced incentives to challenge brand name patents.
PhRMA and BIO, which represent life sciences firms, developed principles about sharing truthful and non-misleading information with payers and providers.
FDA Commissioner Robert Califf has two plans for what he wants to achieve during his tenure. One is long-term. The other ends in early 2017.
PhRMA brings on new members, Amgen partners with Daiichi Sankyo on biosimilar commercialization in Japan; Thomson Reuters to sell science unit